Update on BPA and the FDA

by Matt Shudtz

On Monday, the big news out of FDA was the announcement that they’re going to publish a new assessment of the risks posed by BPA in food packaging, due out by the end of November. Jesse Goodman, FDA’s Chief Scientist, made the announcement at a meeting of the agency’s Science Board, which also heard two presentations by scientists from different offices within FDA working on the new assessment.

Last year, FDA formed a task force to assess the risks of BPA and the task force quickly concluded that “there is a large body of evidence that indicates that FDA-regulated products containing BPA currently on the market are safe and that exposure levels to BPA from food contact materials, including for infants and children, are below those that may cause health effects.” Given the rapid development of new studies on BPA in the diet, it’s a good thing that FDA is taking another comprehensive look at the available science. In the development of their new assessment, FDA ought to use a “weight-of-the-evidence” approach to their work and give due consideration to each study’s funding source and the researchers’ freedom to design and publish their work without sponsor interference.



© 2016 The Center for Progressive Reform